The total sales of Eli Lilly's two brands of tirzepatide, Mounjaro (for blood - sugar control) and Zepbound (for weight loss), were approximately $16.5 billion during the same period
Important considerations include: GLP-1 agonists are generally well-tolerated in people with hypertension They do not typically cause dangerous drops in blood pressure Dehydration from gastrointestinal side effects (nausea, vomiting, diarrhoea) can occasionally affect blood pressure and kidney function, so maintaining adequate fluid intake is important If you take diuretics (water tablets), ACE inhibitors or ARBs for blood pressure, your doctor may monitor you more closely during the initial weeks of GLP-1 therapy Seek medical advice promptly if you experience persistent gastrointestinal symptoms that prevent adequate fluid intake NICE guidance (NG28) supports the use of GLP-1 agonists in people with type 2 diabetes who meet specific criteria, with preference for agents with proven cardiovascular benefits in those with established cardiovascular disease
Many participants in the trials achieved excellent results at 8 mg without needing to escalate to the 12 mg maximum, which suggests that the highest dose is not necessary or appropriate for everyone
Adverse effects were similar to those seen with the GLP-1 receptor agonist class
Future research should include appropriately powered cohort studies or randomized controlled trials (RCTs) to: Investigate the prophylactic efficacy of L-carnitine against preterm infant complications [e.g., sepsis, necrotizing enterocolitis (NEC)]
